Repros Therapeutics Inc.
RPRX
RPRX was delisted on the 31st of January, 2018.
80 hedge funds and large institutions have $379M invested in Repros Therapeutics Inc. in 2014 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 16 reducing their positions, and 13 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 16
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
1% more funds holding
Funds holding: 79 → 80 (+1)
8% less capital invested
Capital invested by funds: $412M → $379M (-$32.8M)
17% less call options, than puts
Call options by funds: $10.6M | Put options by funds: $12.7M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$27.8M |
| 2 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$24M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$15.8M |
| 4 |
DCM
Destrier Capital Management
New York
|
+$3.89M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$27.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$23.8M |
| 3 |
State Street
Boston,
Massachusetts
|
-$11.6M |
| 4 |
WC
Wexford Capital
West Palm Beach,
Florida
|
-$8.41M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$8.24M |
RPRX Hedge Fund Activity: Q1 2014 in Review
80 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics Inc. (RPRX) for Q1 2014, worth a combined $379M — down 8% from $412M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new RPRX positions and 13 closed out — a net gain of 2 holders — while 30 added to existing stakes and 16 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $27.8M. The largest seller was Jennison Associates, exiting entirely with an estimated $27.4M sold.
- 80 institutional investors held Repros Therapeutics Inc. (RPRX) as of Q1 2014, up from 79 in Q4 2013.
- Funds reported $379M of Repros Therapeutics Inc. stock for Q1 2014, down 8% quarter-over-quarter.
- 15 funds opened new Repros Therapeutics Inc. positions in Q1 2014 and 13 closed out, a net change of +2 holders.
- The largest Repros Therapeutics Inc. buyer in Q1 2014 was RA Capital Management, an estimated $27.8M added.
- The largest Repros Therapeutics Inc. seller in Q1 2014 was Jennison Associates, an estimated $27.4M sold.
Based on aggregated 13F filings for Q1 2014.